DE60235995D1 - Aripiprazole Wirkstoff mit niedriger Hygroskopie und Verfahren zu ihrer Herstellung - Google Patents

Aripiprazole Wirkstoff mit niedriger Hygroskopie und Verfahren zu ihrer Herstellung

Info

Publication number
DE60235995D1
DE60235995D1 DE60235995T DE60235995T DE60235995D1 DE 60235995 D1 DE60235995 D1 DE 60235995D1 DE 60235995 T DE60235995 T DE 60235995T DE 60235995 T DE60235995 T DE 60235995T DE 60235995 D1 DE60235995 D1 DE 60235995D1
Authority
DE
Germany
Prior art keywords
aripiprazole
agent
preparation
low hygroscopicity
hygroscopicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60235995T
Other languages
English (en)
Inventor
Takuji Bando
Satoshi Aoki
Junichi Kawasaki
Makoto Ishigami
Youichi Taniguchi
Tsuyoshi Yabuuchi
Kiyoshi Fujimoto
Yoshihiro Nishioka
Noriyuki Kobayashi
Tsutomu Fujimura
Masanori Takahashi
Kaoru Abe
Tomonori Nakagawa
Koichi Shinhama
Naoto Utsumi
Michiaki Tominaga
Yoshihiro Oi
Shohei Yamada
Kenji Tomikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27171631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60235995(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA 2379005 external-priority patent/CA2379005A1/en
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60235995D1 publication Critical patent/DE60235995D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
DE60235995T 2001-09-25 2002-09-25 Aripiprazole Wirkstoff mit niedriger Hygroskopie und Verfahren zu ihrer Herstellung Expired - Lifetime DE60235995D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001290645 2001-09-25
JP2001348276 2001-11-14
CA 2379005 CA2379005A1 (en) 2001-09-25 2002-03-27 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof

Publications (1)

Publication Number Publication Date
DE60235995D1 true DE60235995D1 (de) 2010-05-27

Family

ID=27171631

Family Applications (5)

Application Number Title Priority Date Filing Date
DE60236231T Expired - Lifetime DE60236231D1 (de) 2001-09-25 2002-09-25 Gering hygroskopische Aripiprazol-Substanz (Kristal D) und Herstellungsverfahren
DE60210409T Expired - Lifetime DE60210409T2 (de) 2001-09-25 2002-09-25 Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung
DE60235995T Expired - Lifetime DE60235995D1 (de) 2001-09-25 2002-09-25 Aripiprazole Wirkstoff mit niedriger Hygroskopie und Verfahren zu ihrer Herstellung
DE60236229T Expired - Lifetime DE60236229D1 (de) 2001-09-25 2002-09-25 Gering hygroskopische Aripiprazol-Substanz (Kristal F) und Herstellungsverfahren
DE60236383T Expired - Lifetime DE60236383D1 (de) 2001-09-25 2002-09-25 Gering hygroskopische Aripiprazol-Substanz (Kristal E) und Herstellungsverfahren

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE60236231T Expired - Lifetime DE60236231D1 (de) 2001-09-25 2002-09-25 Gering hygroskopische Aripiprazol-Substanz (Kristal D) und Herstellungsverfahren
DE60210409T Expired - Lifetime DE60210409T2 (de) 2001-09-25 2002-09-25 Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE60236229T Expired - Lifetime DE60236229D1 (de) 2001-09-25 2002-09-25 Gering hygroskopische Aripiprazol-Substanz (Kristal F) und Herstellungsverfahren
DE60236383T Expired - Lifetime DE60236383D1 (de) 2001-09-25 2002-09-25 Gering hygroskopische Aripiprazol-Substanz (Kristal E) und Herstellungsverfahren

Country Status (23)

Country Link
US (20) US20040058935A1 (de)
EP (6) EP1927355B1 (de)
JP (3) JP3760264B2 (de)
CN (16) CN106420627A (de)
AR (2) AR033485A1 (de)
AT (5) ATE465737T1 (de)
AU (1) AU2002334413C1 (de)
BR (1) BR0205391A (de)
CA (6) CA2689052C (de)
CY (1) CY1118195T1 (de)
DE (5) DE60236231D1 (de)
DK (5) DK1419776T4 (de)
ES (5) ES2343179T5 (de)
HU (1) HUP0600141A3 (de)
IL (3) IL153838A0 (de)
MX (1) MXPA03000440A (de)
NO (7) NO328134B1 (de)
PE (1) PE20090124A1 (de)
PL (1) PL225415B1 (de)
PT (5) PT1927356E (de)
SI (4) SI1927355T1 (de)
UA (1) UA84764C2 (de)
WO (1) WO2003026659A1 (de)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
TWI307626B (en) 2002-08-20 2009-03-21 Bristol Myers Squibb Co Aripiprazole complex formulation and method
WO2004043358A2 (en) * 2002-11-08 2004-05-27 Bristol-Myers Squibb Company Formulations of low solubility bioactive agents and processes for making the same
EP1575590B1 (de) 2002-12-27 2007-10-24 Otsuka Pharmaceutical Co., Ltd. Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
ES2250919T5 (es) † 2003-01-09 2010-12-03 Otsuka Pharmaceutical Co., Ltd. Procedimiento de preparación de aripiprazol.
US20060270683A1 (en) * 2003-04-25 2006-11-30 Lohray Braj B Polymorphs of aripiprazole
CN1794994A (zh) 2003-05-23 2006-06-28 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
WO2005009990A1 (en) * 2003-07-25 2005-02-03 Hetero Drugs Limited Aripiprazole crystalline forms
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
DE602004017342D1 (de) 2003-10-23 2008-12-04 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
PL1613598T3 (pl) * 2003-12-16 2012-03-30 Teva Pharma Sposób wytwarzania krystalicznych form aripiprazolu
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
CA2559824A1 (en) 2004-02-05 2006-01-05 Teva Pharmaceutical Industries Ltd. Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril
WO2005077904A1 (en) * 2004-02-05 2005-08-25 Teva Pharmaceutical Industries, Ltd. Process for preparing aripiprazole
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
US20090198059A1 (en) * 2004-09-13 2009-08-06 Chava Satyanarayana Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts
KR101041551B1 (ko) 2004-10-08 2011-06-15 수벤 라이프 사이언시스 리미티드 아리피프라졸 제조를 위해 유용한 신규 중간체와 신규중간체 및 아리피프라졸 제조 방법
CN100338038C (zh) * 2004-10-14 2007-09-19 重庆医药工业研究院有限责任公司 阿立派唑的新晶型及其制备方法
CN102627603A (zh) * 2004-11-18 2012-08-08 斯索恩有限公司 制备结晶阿立哌唑的方法
WO2006053780A1 (en) 2004-11-18 2006-05-26 Synthon B.V. Crystalline aripiprazole solvates
PL1844036T3 (pl) 2005-01-27 2016-02-29 Sandoz Ag Sposób otrzymywania arypiprazolu
EP1686117A1 (de) * 2005-01-27 2006-08-02 Sandoz AG Polymorph und Solvate von Aripiprazol
AU2006224760A1 (en) 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline Type II aripiprazole
AU2006224759A1 (en) † 2005-03-17 2006-09-21 Synthon B.V. Process of making crystalline Type II aripiprazole
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
WO2007004061A1 (en) * 2005-04-15 2007-01-11 Medichem, S.A. Syntheses and preparations of polymorphs of crystalline aripiprazole
CN100432053C (zh) * 2005-06-07 2008-11-12 上海医药工业研究院 阿立哌唑晶型及其制备方法
HUP0500683A3 (en) * 2005-07-14 2009-03-30 Egis Gyogyszergyar Nyilvanosan New arylpiprazole salts for producing pharmaceutical composition
US20070014864A1 (en) * 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
WO2007011349A1 (en) * 2005-07-15 2007-01-25 Teva Pharmaceutical Industries Ltd. Novel granulation process and granulate produced therefrom
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
BRPI0606163A2 (pt) 2005-09-29 2009-05-26 Teva Pharma métodos para preparar aripiprazola anidra forma ii
CZ299485B6 (cs) * 2005-10-11 2008-08-13 Zentiva, A. S. Zpusob výroby aripiprazolu
BRPI0608185A2 (pt) * 2005-12-22 2009-11-17 Teva Pharma processo para redução do tamanho de partìcula de aripiprazol
EP2036545A1 (de) * 2006-01-05 2009-03-18 Teva Pharmaceutical Industries Ltd. Aripiprazol-Tabletten
ATE429906T1 (de) * 2006-01-05 2009-05-15 Teva Pharma Trockene aripiprazolformulierungen
TWI394753B (zh) 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
EP1880714A1 (de) 2006-07-20 2008-01-23 Helm AG Amorphes Aripiprazol und Verfahren zu dessen Herstellung
TR200604349A2 (tr) 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
EP2084133A2 (de) * 2006-09-28 2009-08-05 Cadila Healthcare Limited Verfahren zur herstellung von kristallinem aripiprazol
ES2401603T3 (es) 2006-10-24 2013-04-23 Cambrex Charles City, Inc. Procedimiento para preparar aripiprazol anhidro de tipo l
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
KR101892745B1 (ko) * 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
NZ582415A (en) 2007-07-31 2012-05-25 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
ATE482691T1 (de) 2008-01-23 2010-10-15 Helm Ag Amorphes aripiprazol und verfahren zu seiner herstellung
WO2010079506A2 (en) 2008-06-23 2010-07-15 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of aripiprazole
EP2233471A1 (de) 2009-02-06 2010-09-29 Adamed Sp. z o.o. Salz aus 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4.dihydro-2(1h)-chinolinon mit 5-sulfosalizyklischer säure und herstellungsverfahren
WO2010106551A2 (en) * 2009-03-09 2010-09-23 Neuland Laboratories Ltd. A process for the manufacture of pure anhydrous aripiprazole form b
EP2238976B1 (de) 2009-04-03 2012-06-27 Hexal AG Oraler Film mit 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-chinolin-2-on-Base oder Salze oder Hydrate davon
EP2477609A1 (de) 2009-09-15 2012-07-25 Ratiopharm GmbH Im mund zerfallende pharmazeutische darreichungsform mit aripiprazol
CN102372672B (zh) * 2010-08-24 2014-06-04 重庆圣华曦药业股份有限公司 低吸湿性阿立哌唑晶体iv、制备方法及其应用
CN101948426A (zh) * 2010-09-13 2011-01-19 浙江华海药业股份有限公司 一种制备阿立哌唑晶型b的新方法
JP2012121850A (ja) * 2010-12-09 2012-06-28 Otsuka Pharmaceut Co Ltd アリピプラゾールの経口速溶性組成物
CN102060763B (zh) * 2010-12-27 2012-11-14 齐鲁制药有限公司 微粉型阿立哌唑晶型ⅰ或ⅱ的制备方法
RU2757859C2 (ru) 2011-03-18 2021-10-21 Алкермес Фарма Айэленд Лимитед Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбитана
WO2012131451A1 (en) 2011-03-30 2012-10-04 Jubilant Life Sciences Limited Process for producing aripiprazole in anhydrous type i crystals
KR101340214B1 (ko) 2011-03-31 2013-12-10 주식회사 대웅제약 무수 아리피프라졸 ⅱ형 결정의 제조방법
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
GB2505860B (en) * 2011-06-27 2018-10-31 Shanghai Zhongxi Pharmaceutical Corp Aripiprazole medicament formulation and preparation method therefor
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
CN103172563B (zh) * 2011-12-26 2015-03-25 北京京卫燕康药物研究所有限公司 小粒径的晶型i阿立哌唑的工业化制备
CN102584858B (zh) * 2011-12-31 2014-11-12 广州医药工业研究院 乳酸左旋尤利沙星晶体及其制备方法和用途
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
EP2868319A4 (de) 2012-06-29 2016-02-24 Maruishi Pharma Orale pharmazeutische aripiprazolzubereitung
KR101372840B1 (ko) * 2012-08-02 2014-03-12 주식회사 에스텍파마 무수 아리피프라졸 결정의 제조방법
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
JP2014114243A (ja) * 2012-12-11 2014-06-26 Ohara Yakuhin Kogyo Kk 安定な固形製剤の製造方法
CN107129467A (zh) * 2013-03-26 2017-09-05 江苏恩华药业股份有限公司 阿立哌唑结晶b
AR096131A1 (es) * 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
ES2625613T3 (es) * 2013-04-30 2017-07-20 Otsuka Pharmaceutical Co., Ltd. Preparación sólida oral que comprende aripiprazol y método para producir una preparación sólida oral que comprende aripiprazol
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150093441A1 (en) * 2013-09-30 2015-04-02 Otsuka Pharmaceutical Co., Ltd Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
EP3065700A1 (de) 2013-11-07 2016-09-14 Synthon B.V. Im mund zerfallende pharmazeutische zusammensetzungen mit aripiprazol
EP3119399A4 (de) 2014-03-20 2017-09-27 Alkermes Pharma Ireland Limited Aripiprazolformulierungen mit erhöhten injektionsgeschwindigkeiten
EP2988367B1 (de) * 2014-08-18 2022-09-28 Samsung Electronics Co., Ltd. Antenne für elektronische vorrichtung
LT3185867T (lt) * 2014-08-25 2021-06-10 Alkermes Pharma Ireland Limited Apiprazolo darinių kristalizavimo procesas prailginto atpalaidavimo vaisto formose, skirtose šizofrenijos gydymui
JP6023770B2 (ja) * 2014-10-01 2016-11-09 株式会社パーマケム・アジア アリピプラゾール無水物ｂ形結晶の製造方法
WO2016138536A2 (en) * 2015-02-27 2016-09-01 Tactual Labs Co. Alterable ground plane for touch surfaces
EP3294724A4 (de) * 2015-05-08 2018-11-21 Davuluri, Ramamohan Rao Verbessertes verfahren zur herstellung von aripiprazol mit verringerter partikelgrösse
JP6071083B2 (ja) * 2015-06-12 2017-02-01 大原薬品工業株式会社 安定性が改善された、アリピプラゾールを含有する散剤
JP2015172084A (ja) * 2015-07-06 2015-10-01 大塚製薬株式会社 アリピプラゾールの経口速溶性組成物
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
CN108602774B (zh) 2016-02-19 2021-07-27 南京诺瑞特医药科技有限公司 阿立哌唑的新晶型
TWI665194B (zh) * 2016-02-19 2019-07-11 諾瑞特國際藥業股份有限公司 阿立哌唑的新晶型
EP3426280A4 (de) * 2016-03-10 2019-10-23 The Regents of The University of Michigan Verfahren zur behandlung neurodegenerativer erkrankungen
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
JP6572257B2 (ja) * 2017-05-16 2019-09-04 大塚製薬株式会社 アリピプラゾールの経口速溶性組成物
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
JP7211136B2 (ja) * 2019-02-14 2023-01-24 ニプロ株式会社 錠剤、および、その製造方法
CN110128337A (zh) * 2019-06-10 2019-08-16 岳阳新华达制药有限公司 一种阿立哌唑晶型b的制备方法
KR102128883B1 (ko) 2019-10-02 2020-07-01 (주)삼화바이오팜 고순도 아리피프라졸의 신규 결정형 및 이의 제조방법
WO2021201239A1 (en) 2020-04-01 2021-10-07 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
EP4043008A1 (de) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit aripiprazol
CN117309825B (zh) * 2023-11-30 2024-04-09 四川蜀道建筑科技有限公司 一种透光检测亚甲蓝mb值的设备

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62149664A (ja) 1978-03-30 1987-07-03 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体の製造法
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS55127371A (en) 1980-02-14 1980-10-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4438119A (en) 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
DK588486A (da) 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4771053A (en) 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US5162375A (en) * 1988-05-06 1992-11-10 Beecham Group P.L.C. Treatment of neuronal degeneration with 5HT1A agonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US5053514A (en) * 1988-08-10 1991-10-01 Otsuka Pharmaceutical Company, Limited Cardiotonics
DE3831888A1 (de) 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg Arzneimittel zur behandlung von apoplexia cerebri
US5200410A (en) * 1988-09-20 1993-04-06 Troponwerke Gmbh & Co. Medicaments for the treatment of cerebral apoplexy
FR2637591B1 (fr) * 1988-10-11 1992-10-23 Synthelabo Derives de quinoleinone, leur preparation et leur application en therapeutique
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5073377A (en) * 1988-11-03 1991-12-17 Miles Inc. Method of preparing oral dosage forms with a granulating composition
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
WO1992010200A1 (en) 1990-12-14 1992-06-25 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
CA2067475C (en) * 1991-05-08 2000-10-10 Yasuo Oshiro Carbostyril derivatives and their use
EP0586525B1 (de) 1991-05-20 1997-04-16 PHARMACIA & UPJOHN COMPANY Karboxamido-(1,2n)-karbocyclo-2-aminotetralinderivate
DE4135551A1 (de) 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
US5292766A (en) 1992-03-25 1994-03-08 Eli Lilly And Company Method for improving primary memory and/or learning
AU5446894A (en) 1992-10-23 1994-05-24 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2506547B2 (ja) 1993-06-16 1996-06-12 ミナミ産業株式会社 豆腐のパック詰め装置
JP2959615B2 (ja) 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH07247271A (ja) * 1994-01-21 1995-09-26 Otsuka Pharmaceut Co Ltd ３，４−ジヒドロカルボスチリル誘導体
US5663178A (en) * 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
US5504093A (en) * 1994-08-01 1996-04-02 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication
JP2987484B2 (ja) 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
JPH0940648A (ja) 1995-08-02 1997-02-10 Yamanouchi Pharmaceut Co Ltd 新規な８−（２−アミノアルコキシ）キノリン誘導体
US5766748A (en) 1995-11-30 1998-06-16 Mitsui Chemicals, Inc. Stretched film of lactic acid-based polymer
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
HU229057B1 (en) 1996-05-07 2013-07-29 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
WO1998007426A1 (en) 1996-08-22 1998-02-26 Glaxo Group, Ltd. Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes
WO1998008817A1 (en) 1996-08-27 1998-03-05 American Home Products Corporation 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
JP2002501920A (ja) 1998-02-03 2002-01-22 アメリカン・ホーム・プロダクツ・コーポレイション セロトニン−１ａ受容体作動薬としてのオキサゾール誘導体
JP2001089128A (ja) * 1998-04-10 2001-04-03 Asahi Glass Co Ltd 球状シリカ粒子の製造方法
AU3555099A (en) 1998-04-13 1999-11-01 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
AR015036A1 (es) * 1998-04-29 2001-04-11 American Home Prod Derivados de indolilo antisicoticos, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
JPH11335286A (ja) 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
US20030027817A1 (en) * 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
EP1251854A2 (de) 2000-01-19 2002-10-30 Akzo Nobel N.V. Arzneistoffkombination zur behandlung von depression und zusammenhängenden erkrankungen mit mirtazapine und gepirone
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
JP4197088B2 (ja) 2000-06-05 2008-12-17 電気化学工業株式会社 低密度かつ低ガス透過性六方晶窒化硼素焼結体及びその製造方法
WO2002053140A2 (en) 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
ATE452642T1 (de) 2001-06-19 2010-01-15 Norbert Mueller Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2003238393A (ja) 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
CN1794994A (zh) 2003-05-23 2006-06-28 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
DE602004017342D1 (de) 2003-10-23 2008-12-04 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
EP2049530A2 (de) 2006-07-12 2009-04-22 Nerviano Medical Sciences S.r.l. Kristallines nemorubicinhydrochlorid
US9149434B2 (en) 2007-12-03 2015-10-06 Tomita Pharmaceutical Co., Ltd. Core particle for pharmaceutical preparation
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament

Also Published As

Publication number Publication date
US20140309236A1 (en) 2014-10-16
IL153838A0 (en) 2003-07-31
BR0205391A (pt) 2003-07-29
AR056503A2 (es) 2007-10-10
DK1927355T3 (da) 2010-07-19
EP1330249A1 (de) 2003-07-30
JP2006070045A (ja) 2006-03-16
US20210395204A1 (en) 2021-12-23
EP1927355A1 (de) 2008-06-04
CN101434573A (zh) 2009-05-20
US20200123110A1 (en) 2020-04-23
ATE465737T1 (de) 2010-05-15
MXPA03000440A (es) 2003-10-06
US20120316180A1 (en) 2012-12-13
ES2343602T3 (es) 2010-08-04
DE60236383D1 (de) 2010-06-24
US20120315302A1 (en) 2012-12-13
ES2343220T3 (es) 2010-07-26
EP1925308B1 (de) 2016-08-31
NO336262B1 (no) 2015-07-06
CN101792415A (zh) 2010-08-04
US8580796B2 (en) 2013-11-12
ATE322269T1 (de) 2006-04-15
PT1927356E (pt) 2010-05-24
CN106420640A (zh) 2017-02-22
EP1927357A3 (de) 2008-06-11
US20070203152A1 (en) 2007-08-30
ES2343179T3 (es) 2010-07-26
CN101434574A (zh) 2009-05-20
CN1699346A (zh) 2005-11-23
DE60210409T2 (de) 2006-11-16
EP1927356A1 (de) 2008-06-04
CA2688915C (en) 2011-02-01
JP4614870B2 (ja) 2011-01-19
AU2002334413C9 (en) 2015-04-09
CN1463191A (zh) 2003-12-24
SI1927356T1 (sl) 2010-07-30
CN101434573B (zh) 2011-12-07
HUP0600141A3 (en) 2008-03-28
EP1419776A8 (de) 2004-09-01
US20120016123A1 (en) 2012-01-19
ES2343219T3 (es) 2010-07-26
CN101579344B (zh) 2012-05-30
ES2261750T3 (es) 2006-11-16
DK1330249T3 (da) 2006-08-07
EP1419776A3 (de) 2004-06-16
CN106420627A (zh) 2017-02-22
UA84764C2 (en) 2008-11-25
CN101423492B (zh) 2013-08-28
CN1817882B (zh) 2011-09-07
CA2688934C (en) 2011-05-17
NO336265B1 (no) 2015-07-06
PT1330249E (pt) 2006-06-30
CN101579344A (zh) 2009-11-18
US8399469B2 (en) 2013-03-19
DK1419776T3 (da) 2010-07-05
US20120000998A1 (en) 2012-01-05
EP1925308A1 (de) 2008-05-28
SI1330249T1 (sl) 2006-10-31
CA2689051C (en) 2011-03-08
US20190225584A1 (en) 2019-07-25
EP1419776B2 (de) 2017-07-19
DK1927357T3 (da) 2010-08-16
DE60210409D1 (de) 2006-05-18
US20040058935A1 (en) 2004-03-25
EP1927357B1 (de) 2010-05-12
CN101574347A (zh) 2009-11-11
CY1118195T1 (el) 2017-06-28
CN1817882A (zh) 2006-08-16
CA2688860A1 (en) 2003-04-03
PT1927355E (pt) 2010-06-11
DE60236229D1 (de) 2010-06-10
EP1927357A2 (de) 2008-06-04
CN101423492A (zh) 2009-05-06
US20070202181A1 (en) 2007-08-30
CA2689052C (en) 2011-02-15
CN101574347B (zh) 2012-02-29
US9359302B2 (en) 2016-06-07
PE20090124A1 (es) 2009-03-07
AU2002334413C1 (en) 2021-08-12
US20070203151A1 (en) 2007-08-30
US8901130B2 (en) 2014-12-02
CN106692151A (zh) 2017-05-24
SI1419776T2 (sl) 2017-12-29
ATE467416T1 (de) 2010-05-15
PT1927357E (pt) 2010-06-08
US8642760B2 (en) 2014-02-04
US20070212421A1 (en) 2007-09-13
JP2003212852A (ja) 2003-07-30
NO20081632L (no) 2003-01-17
ATE465736T1 (de) 2010-05-15
CN101434574B (zh) 2011-12-14
IL188455A0 (en) 2008-03-20
US20070213343A1 (en) 2007-09-13
NO20091689L (no) 2003-01-17
CA2426921C (en) 2011-03-15
US20070203150A1 (en) 2007-08-30
ES2343179T5 (es) 2017-10-19
NO20030247L (no) 2003-01-17
EP1419776B1 (de) 2010-04-14
NO336264B1 (no) 2015-07-06
DK1927356T3 (da) 2010-07-26
US20160251315A1 (en) 2016-09-01
CN101579343B (zh) 2012-04-18
SI1419776T1 (sl) 2010-07-30
US20150225347A1 (en) 2015-08-13
HUP0600141A2 (hu) 2006-05-29
CA2688915A1 (en) 2003-04-03
AR033485A1 (es) 2003-12-26
US8703773B2 (en) 2014-04-22
EP1927356B1 (de) 2010-04-28
NO328134B1 (no) 2009-12-14
CN101574348B (zh) 2012-02-22
CA2426921A1 (en) 2003-04-03
CA2689051A1 (en) 2003-04-03
PL360900A1 (en) 2004-09-20
DE60236231D1 (de) 2010-06-10
EP1419776A9 (de) 2004-09-08
US20140030523A1 (en) 2014-01-30
NO20081631L (no) 2003-01-17
SI1927355T1 (sl) 2010-07-30
EP1927355B1 (de) 2010-04-28
JP2004256555A (ja) 2004-09-16
CN101574348A (zh) 2009-11-11
US8017615B2 (en) 2011-09-13
US8901303B2 (en) 2014-12-02
CA2688934A1 (en) 2003-04-03
PL225415B1 (pl) 2017-04-28
US8993761B2 (en) 2015-03-31
CN101434575A (zh) 2009-05-20
NO20081626L (no) 2003-01-17
NO20081633L (no) 2003-01-17
US7910589B2 (en) 2011-03-22
NO336679B1 (no) 2015-10-19
PT1419776E (pt) 2010-04-28
JP3760264B2 (ja) 2006-03-29
ATE464050T1 (de) 2010-04-15
WO2003026659A1 (en) 2003-04-03
NO20030247D0 (no) 2003-01-17
US10150735B2 (en) 2018-12-11
EP1330249B1 (de) 2006-04-05
AU2002334413B2 (en) 2004-11-04
EP1419776A2 (de) 2004-05-19
JP3750023B2 (ja) 2006-03-01
US20120316179A1 (en) 2012-12-13
CN101579343A (zh) 2009-11-18
NO20081627L (no) 2003-01-17
DK1419776T4 (en) 2017-09-04
CN101423493A (zh) 2009-05-06
IL153838A (en) 2008-04-13
CA2689052A1 (en) 2003-04-03
US20070213344A1 (en) 2007-09-13
NO336263B1 (no) 2015-07-06

Similar Documents

Publication Publication Date Title
DE60235995D1 (de) Aripiprazole Wirkstoff mit niedriger Hygroskopie und Verfahren zu ihrer Herstellung
DE50101931D1 (de) Substituierte sulfonylaminomethylbenzoesäure(derivate) und verfahren zu ihrer herstellung
DE60221201D1 (de) Polyoxyalkylen-derivate und Verfahren zu ihrer Herstellung
DE60233058D1 (de) Silsesquioxanderivate und verfahren zu ihrer herstellung
DE60231548D1 (de) N; formkörper und verfahren zu ihrer herstellung
DE60121399D1 (de) Aminoverbindung und Verfahren zu ihrer Herstellung
DE60201475D1 (de) Mit Polyhydroxyalkanoat beschichtetes Liposom und Verfahren zu seiner Herstellung
DE60221950D1 (de) Kieselsäure sowie Verfahren zu ihrer Herstellung
DE60129519D1 (de) Wasserabsorbierendes Mittel und Verfahren zu seiner Herstellung
DE60016863D1 (de) Wässrige Emulsion und Verfahren zu ihrer Herstellung
DE60217203D1 (de) Poröse Teilchen, wässrige Dispersionen und Verfahren zu ihrer Herstellung
DE60205047D1 (de) Poröse Teilchen, wässrige Dispersionen und Verfahren zu ihrer Herstellung
DE60102889T2 (de) Wasserlösliche, Wasser- und Ölabweisende Zusammensetzung sowie Verfahren zu ihrer Herstellung
DE10393704D2 (de) Nancomposite, Verfahren zu ihrer Herstellung und ihre Verwendung
DE60124987D1 (de) Hybrider Steckverbinder und Verfahren zu seiner Herstellung
DE60111195D1 (de) Wässerige formulierungen und verfahren zu ihrer herstellung
DE60318167D1 (de) Arzneiform und Verfahren zu ihrer Herstellung
DE60226677D1 (de) Saw-einrichtung und verfahren zu ihrer herstellung
DE60206177D1 (de) Fluorierte ionomere sowie verfahren zu ihrer herstellung
DE60132390D1 (de) Biosensor und Verfahren zu seiner Herstellung
ATE290366T1 (de) Pharmazeutische formulierung mit überdecktem geschmack und verfahren zu ihrer herstellung
ATE315076T1 (de) Bleichmittelzusammensetzung mit verbesserter stabilität und verfahren zu ihrer herstellung
DE60108054D1 (de) Kautschukzusammensetzung und Verfahren zu ihrer Herstellung
DE60316383D1 (de) Aminzusammensetzung und Verfahren zu ihrer Herstellung
DE60207902T2 (de) Isocyanuratverbindung und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
8363 Opposition against the patent